Compliance and persistance;Compliance et persistance

Journal Francais d'Ophtalmologie

Volumn 29, Issue 2, 2006, Pages 216-225

  Detry Morel, M ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Compliance; Glaucoma; Ocular hypertension; Persistence; Quality of life

Indexed keywords

ENVIRONMENTAL FACTOR; HUMAN; INTRAOCULAR HYPERTENSION; MONITORING; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; REVIEW; SELF REPORT; SURVIVAL;

EID: 33644821745     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0181-5512(06)73775-5     Document Type: Article

References (94)

1. Schwartz GF. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol, 2005;16:114-21.
2. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet, 2004;363:1711-20.
3. nd ed. Savona, Italy: Editrice DOGMA, 2003.
4. The Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol, 1998;126:498-505.
5. The Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol, 1998;126:487-97.
6. The Advanced Glaucoma Intervention Study (AGIS):9. Comparison of glaucoma outcomes in black and white patients within treatment groups. Am J Ophthalmol, 2001;132:311-20.
7. Lichter PR, Musch DC, Gillepsie BW, Guire KE, Janz NK, Wren PA, Mills RP and the CIGTS Study Group. Interim Clinical Outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medication or surgery. Ophthalmology, 2001;108:1943-53.
8. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol, 2002;120:1268-79.
9. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol, 2003;121:48-56.
10. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure as an independent risk factor in patients with glaucoma. J Glaucoma, 2000;9:134-42.
11. Weinreb RN, Tsai GS. Laser trabeculoplasty. In: Ritch R, Shields MB, Krupin T eds. The Glaucomas. St. Louis, Mosby 1996; p. 1575-90.
12. Camras CB, Toris CB, Tamesis RR. Efficacy and adverse effects of medications used in the treatment of glaucoma. Drugs Aging, 1999;15:377-88.
13. Béchetoille A. Chirurgie des glaucomes chroniques de l'adulte. In: Les glaucomes Béchetoille A, Japperenard (ISBN 2-9501926-3-7): 2000; p. 279-324.
14. Migdal CS, Hitchings RA. Control of chronic simple glaucoma with primary, surgical and laser treatment. Trans Ophthalmol Soc UK, 1986;105:653-6.
15. Jay JL, Murray SB. Early trabeculectomy versus conventional management in primary open angle glaucoma. Br J Ophthalmol, 1988;72:881-9.
16. Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J, 1995;130:572-9.
17. Baudouin C, Béchetoille A, Bron A, Denis P, Nordmann JP, Renard JP et al. Intérêt de la mesure de la qualité de vie (QDV) et de l'observance thérapeutique chez les patients atteints de glaucome chronique à angle ouvert. J Fr Ophtalmol, 2000;23:1057-64.
18. Vincent PA. Patients'viewpoint of glaucoma therapy. Sight-Saving Rev, 1972;42:213-21.
19. Demailly P, Zoute C, Castro D. Personnalités et glaucome chronique. J Fr Ophtalmol, 1989;12:595-601.
20. Hamelin N, Blatrix C, Brion F, Mathieu C, Goemaere I, Nordmann JP. Comment les patients réagissent-ils à la découverte d'un glaucome ? J Fr Ophtalmol, 2002;25:795-8.
21. Bour T, Blanchard F, Segal A. Observance thérapeutique et vécu du glaucome primitif à angle ouvert. À propos de 341 cas dans la Marne. J Fr Ophtalmol, 1993;16:380-91.
22. Livingston P, McCarty C, Taylo H. Knowledge, attitudes, and self care practices associated with age related eye disease in Australia. Br J Ophthalmol, 1998;82:780-5.
23. Deokule S, Sadiq S, Shah S. Chronic open angle glaucoma: patient awareness of the nature of the disease, topical medication, compliance and the prevalence of systemic symptoms. Ophthalmic Physiol Opt, 2004;24:9-15.
24. Ramachandran VS, Gregoryb RL. Perceptual filling in of artificially induced scotomas in human vision. Nature, 1991;350:699-702.
25. Das A, Gilbert CD. Long-range horizontal connections and their role in cortical reorganization revealed by optical recording of cat primary visual cortex. Nature, 1995;375:780-4.
26. Safran AB. Scotomes : le point de vue du patient et le point de vue du médecin. Cela n'a rien à voir. Klin Monatsbl Augenheilkd, 1997;210:316-8.
27. Zimmerman TJ, Zalta AH. Facilitating patient compliance in glaucoma therapy. Surv Ophthalmol, 1983;28(Suppl):252-7.
28. Gramer E. Compliance des patients et traitement du glaucome. Comptes-rendus du Congrès Rottach-Engern (Allemagne). Distribué par Lab Chauvin, 1991.
29. Alward PD, Wilenski JT. Determination of Acetazolamide compliance in patients with glaucoma. Arch Ophthalmol, 1981;99:1973-6.
30. Kass MA, Meltzer DW, Gordon M. A miniature compliance monitor for eyedrop medication. Arch Ophthalmol, 1984;102:1550-4.
31. Kass MA, Meltzer DW, Gordon M, Cooper D, Goldberg J. Compliance with topical pilocarpine treatment. Am J Ophthalmol, 1986;101:515-23.
32. Kass MA. Compliance with topical timolol treatment. Am J Ophthalmol, 1987;103:188-93.
33. Norell SE. Monitoring compliance with pilocarpine therapy. Am J Ophthalmol, 1981;92:727-31.
34. Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol, 1986;101:524-30.
35. Kass MA. Patient administration of eyedrops. II. Observation. Ann Ophthalmol, 1982;14:889-93.
36. Granström PA. Glaucoma patients not compliant with their drug therapy: clinical and behavioural aspects. Br J Ophthalmol, 1982;66:464-70.
37. Granström PA, Norell S. Visual ability and drug regimen: relation to compliance with glaucoma therapy. Acta Ophthalmologica, 1983;61:206-19.
38. Siegel LI, Kass MA, Gordon M, Meltzer D. Compliance with topical timolol. IOVS, 1985; 26(Suppl):125.
39. Norell SE. Accuracy of patient interviews and estimates by clinical staff in determining medication compliance. Sci Med, 1981;15:57-61.
40. Kass MA. Part I. Patient administration of eyedrops: interview. Ann Ophthalmol 1982;14:775-9.
41. Brown MM, Brown GC, Spaeth GL. Improper topical self- administration of ocular medication among patients with glaucoma. Can J Ophthalmol, 1984;19:2-5.
42. Hosoda M, Yamabayashi S, Furuta M, Tsukahara S. Do glaucoma patients use eye drops correctly? J Glaucoma, 1995;4:202-6.
43. Bloch S, Rosenthal AR, Friedman A, Calcarolla P. Patient compliance in glaucoma. Br J Ophthalmol, 1977;61:531-4.
44. Mac Kean J.M, Elkington AR. Compliance with treatment of patients with chronic open angle glaucoma. Br J Ophthalmol, 1983;67:46-9.
45. Rocheblave A. La coopération des malades porteurs d'un glaucome chronique primitive à angle ouvert. J Fr Ophtalmol, 1983;6:837-41.
46. Gurwitz J, Glynn R, Monane N. Treatment for Glaucoma: adherences by the elderly. Am J Public Health, 1993;83:711-6.
47. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg, 1995;26:233-6.
48. Rotchford AP, Murphy KM. Compliance with timolol treatment in glaucoma. Eye, 1998;12:234-6.
49. Wane AM, Ndiaye MR, Wade A, Ndiaye PA, Ba ME, de Medeiros ME et al. L'observance au traitement médical dans le glaucome primitif à angle ouvert. Résultats préliminaires. J Fr Ophtalmol, 2003;26:1039-44.
50. Roth HP, Caron HS. Accuracy of doctor's estimates and patient's statement on adherence to a drug regimen. Clin Pharmacol Ther, 1978;23:361-70.
51. Alvan G, Gaissendorff B, Seideman P, Widmark K, Widmark J. Absorption of ocular timolol. Clin Pharmacokint, 1980;5:95-100.
52. Naacke H, Baudouin C. Le patient glaucomateux et son traitement : qu'en est-il réellement ? J Fr Ophthalmol, 1999;22:99-101.
53. Davidson SI, Akingbehin T. Compliance in ophthalmology. Trans Ophthalmol Soc UK, 1980;100:286-90.
54. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma, 2003;12:393-8.
55. Kosoko O, Quigley HA, Vitale S, Enger C, Kerrigan L, Tielsch JM. Risk factors for non-compliance with glaucoma follow-up visits in a residents'eye clinic. Ophthalmology, 1998;105:2105-11.
56. Wandel T, Charap A, Lewis RA, Partamian L, Cobb S, Lue JC et al. Glaucoma treatment with once-daily levobunolol. Am J Ophthalmol, 1986;101:298-304.
57. Amon M, Menapace R, Wedrich A, Radax U. Aspects of glaucoma patient care and its impacts on compliance. Spektrum Augenneilkd, 1990;4:5-8.
58. Kessels RP. Patient's memory for medical information. J R Soc Med, 2003;96:219-22.
59. Ley P. Communicationg with patients: improving communication, satisfaction and compliance. New York: Croom Helm, 1988.
60. Feldman RM. Conjunctival hyperhemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther, 2003;19:23-35.
61. Bigger JF. A comparison of patient compliance in treated vs untreated ocular hypertension. Trans Am Acad Ophthalmol Otolaryngol, 1976;81:277-85.
62. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol, 2003;13(Suppl 4):S44-52.
63. Schwartz GF. Persistency and tolerability of ocular hypotensive agents: population-based evidence in the management of glaucoma. Am J Ophthalmol, 2004;137(Suppl 1):S1-2.
64. Dasgupta S, Oates V, Bookhart BK, Vaziri B, Schwartz GF, Mozaffari E. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care, 2002;8(Suppl):S255-261.
65. Shaya FT, Mullins CD, Wong W, Cho J. Discontinuation rates of topical glaucoma medications in a managed care population. Am J Manag Care, 2002;8(Suppl):S271-7.
66. Spooner JJ, Bullano MF, Ikeda LI. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care, 2002;8(Suppl):S262-70.
67. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther, 2003;25:1172-85.
68. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol, 2004;137(Suppl):S3-12.
69. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol, 2004;137:S13-6.
70. Fiscella RG. Persistency with glaucoma medication. Correspondance. Am J Ophthalmol, 2004;138:1093.
71. Zhou Z, Althin R, Sforzolini S, Dhawan R. Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom. Br J Ophthalmol, 2004;88:1391-4.
72. Day DG, Schacknow PN, Sharpe ED, Ellyn JC, Kulze JC, Threll AB et al. A persistency and economic analysis of latanoprost, bimatoprost or beta-blockers in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther, 2004;20:383-92.
73. Platt R, Reardon G, Mozaffari E. Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottele size. Am J Ophthalmol, 2004;137:S17-S23.
74. Stewart WC. Factors associated with visual loss in patients with advanced glaucomatous changes on the optic nerve head. Am J Ophthalmol, 1993;116:176-81.
75. Hattenhauer MG, Johnson DH, Ing HH, Herman DC, Hodge DO, Yawn BP. The probability of blindness from open-angle glaucoma. Ophthalmology, 1998;105:2099-103.
76. Ashburn FS, Goldberg I, Kass MA. Compliance with ocular therapy. Surv Ophthalmol, 1980;24:237-48.
77. Spaeth GL. Visual loss in a glaucoma clinic. I. Sociological considerations. Invest Ophthalmol, 1970;9:73-82.
78. Norell SE. Improving medication compliance: a randomised clinical trial. Br Med J, 1979;2:1031-3.
79. Kim S, Stewart J, Edmond J, Reynolds A, Motuz Leen M, Mills R. Effect of brief education program on glaucoma patients. J Glaucoma, 1997;6:146-51.
80. Rendell J. Effect of health education on patient's beliefs on glaucoma and compliance. Insight, 2000;4:112-8.
81. Cooper J. Improving compliance with glaucoma eye-drop treatment. Nursing Times, 1996;92:36-7.
82. Jampel HD, Schwartz GF, Robin AL, Abrams DA, Johnson E, Miuller RB. Patient preferences for eye drop characteristics. A willingness- to- pay analysis. Arch Ophthalmol, 2003;121:540-6.
83. Busche S, Gramer E. Improved eyedrop administration and compliance in glaucomatous patients. A clinical study. Klin Monatsbl Augenheilkd, 1997;211:257-62.
84. Schenker H, Maloney S, Liss C, Gormley G, Hartenbaum D. Patient preference, efficacy, and compliance with timolol maleate ophthalmic Gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma. Clin Therapeutics, 1999;21:138-47.
85. Chang JS, Lee DA, Petursson G, Spaeth GL, Zimmerman TZ, Hoskins HD et al. The effect of a glaucoma medication reminder cap on patient compliance and intraocular pressure. J Ocul Pharmacology, 1991;7:117-24.
86. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol, 1994;112:1437-45.
87. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol, 1994;112:1446-54.
88. Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology, 1994;101:454-60.
89. Baudouin C. Side effects of antiglaucoma drugs on the ocular surface. Curr Opin Ophthalmol, 1996;7:80-6.
90. Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint Jean M et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs. Human and animal studies. Ophthalmology, 1999;106:556-63.
91. Pisella PJ, Fillacier K, Elena PP, Debasch C, Baudoin C. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res, 2000;32:3-8.
92. Tielsch JM, Katz J, Singh K, Quigley HA, Gottsch JD, Javitt JC et al. A population baed evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Ophthalmol, 1991;134:1102-10.
93. David R, Stone D. The prevalence of glaucoma in a homogeneous African population. Rec Adv Glaucoma, 1984;145-53.
94. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt JC. Racial variations in the prevalence of primary open angle glaucoma: the Baltimore Eye Survery. JAMA, 1991;266:369-74.